Heart failure & cardiomyopathies
Age Dependency of Cardiovascular Outcomes With the Amyloidogenic pV142I Transthyretin Variant Among Black Individuals in the US
Authors' conclusion
In this study, age-specific risks were provided for relevant outcomes with the pV142I variant. Despite a relatively benign course during earlier years, Black individuals who carry the pV142I variant surviving into later life may be particularly vulnerable.
Study context
- Population
- Black participants of the Atherosclerosis Risk in Communities (ARIC) study attending visit 1 (1987–1989), US124 carriers
- Participants
- 3,856 participants
- Exposure
- pV142I carriers vs non-carriers
- Carriersn = 124
- Outcome
- 10-year absolute risk differences for AF, HF hospitalization, mortality, and HF hospitalization or mortality, for each year between ages 53 and 80 years
- Follow-up
- Median 27.6 years
Methodological detailscommunity-based cohort (ARIC)
- Community-based cohort (ARIC)
Main finding
As reported in the abstract
10-year absolute risk difference, ages 53-80 years
- 10-year absolute risk difference increased over time for each outcome
- Significance emerged near age 65 years for atrial fibrillation (AF)
- Significance emerged near age 70 years for heart failure (HF) hospitalization
- Significance emerged near age 75 years for mortality
- Adjusted for first 5 principal components of ancestry and sex
Observational data: associations, not effects.
Further findings
| Outcome | Absolute risk difference (95% CI) | |
|---|---|---|
| HF hospitalization or death among participants surviving to age 80 years · 5 and 10 yearsCarriersvs Non-carriers5 years | 20% (2%–37%) | |
| HF hospitalization or death among participants surviving to age 80 years · 5 and 10 yearsCarriersvs Non-carriers10 years | 24% (1%–47%) | |
| −200204060Difference (linear scale) |
- HF hospitalization or death among participants surviving to age 80 years — Carriers needed to identify at age 80 years to attribute 1 HF hospitalization or death over the following decade
- 4
Original publication
Age Dependency of Cardiovascular Outcomes With the Amyloidogenic pV142I Transthyretin Variant Among Black Individuals in the US. JAMA Cardiol. Published 1 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →